The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease
Ingo Diel, Ada Braun(Amgen (United States)), Alison Stopeck(National Cancer Centre Japan), Roger von Moos(Kantonsspital Graubünden), Andrew Spencer(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), François Goldwasser(Délégation Paris 5), Günther Steger(Barwon Health), Amy Feng(Amgen (United States)), Jean‐Jacques Body(Université Libre de Bruxelles), Saroj Vadhan‐Raj(The University of Texas MD Anderson Cancer Center)
Cited by 53
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719